Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
We're tracking Insilico Medicine's market expansion
16 signals in the last 90 days.
How Insilico Medicine's international expansion compares to its competitors
Insilico MedicineYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Insilico MedicineYou | 0 | 0 | — | 0 | 0 |
Machine Learning Engineer
View postingAbu Dhabi, Abu Dhabi Emirate, United Arab Emirates · last mo.
Business Development Manager - AI Platform Technologies
View postingTokyo, Japan · 2mo ago
Clinical Project Manager (Oncology) Consultant
View postingUnited States · 2mo ago
Most frontier models continue to miss the mark on critical ADMET and toxicity tasks. Domain expertise isn't solved by prompt tuning alone, it requires specialized training.Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a drug discovery powerhouse. Despite its small footprint, it is now delivering State-of-the-Art (SOTA) results that rival or surpass models ten times its size.We’re ready to help you integrate these models dire ...
Active
Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a drug discovery powerhouse. Despite its small footprint, it is now delivering State-of-the-Art (SOTA) results that rival or surpass models ten times its size.
Active
Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a drug discovery powerhouse. Despite its small footprint, it is now delivering State-of-the-Art (SOTA) results that rival or surpass models ten times its size.
ActiveInsilico Medicine established the industry's first Longevity Board, led by Eli Lilly's Andrew Adams, to oversee AI-driven aging research and drug discovery targeting biological aging processes and healthspan extension.
Insilico Medicine launches industry's first Longevity Committee to provide scientific oversight for AI-driven aging research and drug discovery, focusing on dual-purpose targets addressing aging and disease mechanisms.
Insilico Medicine nominated ISM0387, its 30th AI-driven preclinical candidate and first developed in UAE, targeting glioblastoma with MTA-cooperative PRMT5 inhibition, completed in 12 months using generative AI platform.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Insilico Medicine's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
